These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3733 related articles for article (PubMed ID: 32849662)

  • 21. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
    Braendstrup P; Levine BL; Ruella M
    Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia.
    Qayed M; Bleakley M; Shah NN
    Curr Opin Hematol; 2021 Nov; 28(6):373-379. PubMed ID: 34508031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
    Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
    Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
    Myers RM; Devine K; Li Y; Lawrence S; Leahy AB; Liu H; Vernau L; Callahan C; Baniewicz D; Kadauke S; McGuire R; Wertheim GB; Kulikovskaya I; Gonzalez VE; Fraietta JA; DiNofia AM; Hunger SP; Rheingold SR; Aplenc R; June CH; Grupp SA; Wray L; Maude SL
    Blood Adv; 2024 May; 8(9):2182-2192. PubMed ID: 38386999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.
    Safarzadeh Kozani P; Safarzadeh Kozani P; O'Connor RS
    Mol Cancer Ther; 2021 Jul; 20(7):1223-1233. PubMed ID: 33903140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T-cells in acute lymphoblastic leukemia: Current results.
    Dourthe ME; Baruchel A
    Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 34. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
    Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
    Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
    Aldoss I; Shan H; Yang D; Clark MC; Al Malki M; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
    Transplant Cell Ther; 2024 Aug; 30(8):788.e1-788.e9. PubMed ID: 38876428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
    Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.
    Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P
    Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
    Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
    Front Immunol; 2019; 10():2664. PubMed ID: 31798590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 187.